Novartis To Pay $390M To Settle Justice Department Suit Over Alleged Specialty Pharmacy Kickbacks

In other news about the drug company, the Food and Drug Administration finds no evidence that Novartis' Parkinson's disease treatment, Stalevo, increases heart risks.